Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy significant other | 1,381 |
Reported balance
After 2026-08-17 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-08-17 · Grant · Acquired 1,381 · Balance 1,381 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11: 460 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 461 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy significant other | 160 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 160 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8: 160 restricted stock units vest on 8/15/2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy significant other | 77 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 77 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9: 38 restricted stock units vest on 2/3/2027, and 39 restricted stock units vest on 2/3/2028. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy significant other | 621 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 621 F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10: 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028. |
| Common StockSEC Table I · non-derivative | Direct | 2,680 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,680 |
| Common StockSEC Table I · non-derivative | IndirectBy significant other | 576 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 576 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | IndirectBy significant other | 4,472 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 4,472 F1: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | IndirectBy significant other | 2,076 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 2,076 F1: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.52 · Expires 2029-08-15 | IndirectBy significant other | 2,104 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 2,104 F1: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | IndirectBy significant other | 1,084 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 1,084 F2: Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.91 · Expires 2034-08-15 | IndirectBy significant other | 1,468 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 1,468 F3: Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.05 · Expires 2035-02-03 | IndirectBy significant other | 344 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 344 F4: Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.60 · Expires 2035-08-15 | IndirectBy significant other | 2,735 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 2,735 F5: Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.05 · Expires 2035-02-03 | Direct | 2,415 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 2,415 F1: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.96 · Expires 2035-10-30 | Direct | 3,777 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 3,777 F6: This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
F2: Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
F3: Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
F4: Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
F5: Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
F6: This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
F7: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F8: 160 restricted stock units vest on 8/15/2027.
F9: 38 restricted stock units vest on 2/3/2027, and 39 restricted stock units vest on 2/3/2028.
F10: 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.
F11: 460 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 461 restricted stock units vest on 8/17/2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 20:47 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 1,381 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000131 · form4.xml · derivative · entry 15 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 1,381 Underlying: Common Stock · 1,381 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 460 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 461 restricted stock units vest on 8/17/2029. F11 · derivative.expiration_date: 460 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 461 restricted stock units vest on 8/17/2029. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:12 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 311 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000113 · form4.xml · derivative · entry 15 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 621 Underlying: Common Stock · 311 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028. F11 · derivative.expiration_date: 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:12 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 160 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000113 · form4.xml · derivative · entry 13 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 160 Underlying: Common Stock · 160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: 160 restricted stock units vest on each of 8/15/2026 and 8/15/2027. F9 · derivative.expiration_date: 160 restricted stock units vest on each of 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:12 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 118 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000113 · form4.xml · derivative · entry 12 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 0 Underlying: Common Stock · 118 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8 · derivative.exercise_date: 118 restricted stock units vest on 8/15/2026. F8 · derivative.expiration_date: 118 restricted stock units vest on 8/15/2026. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:12 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 213 | $72.40 | $15,421.20 |
DisclosureSEC source: 0000914190-26-000113 · form4.xml · nonDerivative · entry 3 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 576 Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 20:12 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 589 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000113 · form4.xml · nonDerivative · entry 2 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2026 Filed May 12, 2026 20:04 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,636 | $0.00 Strike: $47.60 | $0.00 |
DisclosureSEC source: 0000914190-26-000092 · form4.xml · derivative · entry 6 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 0 Underlying: Common Stock · 6,636 shares Expires 2026-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| May 08, 2026 Filed May 12, 2026 20:04 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 6,636 | $48.28 | $320,386.08 |
DisclosureSEC source: 0000914190-26-000092 · form4.xml · nonDerivative · entry 3 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 200 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.19 to $48.31, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2026 Filed May 12, 2026 20:04 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 6,636 | $47.60 | $315,873.60 |
DisclosureSEC source: 0000914190-26-000092 · form4.xml · nonDerivative · entry 2 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 6,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:57 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,976 | $59.11 | $116,791.48 |
DisclosureSEC source: 0000914190-26-000030 · form4.xml · nonDerivative · entry 2 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 200 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.091 to $59.1390, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 23:30 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 38 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000011 · form4.xml · derivative · entry 15 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 77 Underlying: Common Stock · 38 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028. F10 · derivative.expiration_date: 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 23:30 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 16 | $64.63 | $1,034.08 |
DisclosureSEC source: 0000914190-26-000011 · form4.xml · nonDerivative · entry 3 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 2,176 Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 23:30 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 38 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000011 · form4.xml · nonDerivative · entry 2 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 2,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 3,777 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0000914190-25-000019 · form4.xml · derivative · entry 4 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,777 Underlying: Common Stock · 3,777 shares Expires 2035-10-30 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 1,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000019 · form4.xml · nonDerivative · entry 1 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,680 Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 2,735 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001062993-25-014701 · form4.xml · derivative · entry 16 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 2,735 Underlying: Common Stock · 2,735 shares Expires 2035-08-15 F13 · derivative.exercise_date: Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 932 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014701 · form4.xml · derivative · entry 15 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 932 Underlying: Common Stock · 932 shares Expires not disclosed F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12 · derivative.exercise_date: 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028. F12 · derivative.expiration_date: 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 160 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014701 · form4.xml · derivative · entry 13 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 320 Underlying: Common Stock · 160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: 160 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027. F10 · derivative.expiration_date: 160 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 119 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014701 · form4.xml · derivative · entry 12 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 118 Underlying: Common Stock · 119 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: 119 restricted stock units vest on 8/15/2025 and 118 restricted stock units vest on 8/15/2026. F9 · derivative.expiration_date: 119 restricted stock units vest on 8/15/2025 and 118 restricted stock units vest on 8/15/2026. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 101 | $53.60 | $5,413.60 |
DisclosureSEC source: 0001062993-25-014701 · form4.xml · nonDerivative · entry 3 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 2,154 Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 279 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014701 · form4.xml · nonDerivative · entry 2 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 2,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,280 | $0.00 Strike: $44.33 | $0.00 |
DisclosureSEC source: 0001062993-25-011400 · form4.xml · derivative · entry 5 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 0 Underlying: Common Stock · 1,280 shares Expires 2025-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,280 | $49.77 | $63,704.83 |
DisclosureSEC source: 0001062993-25-011400 · form4.xml · nonDerivative · entry 3 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 1,976 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 49.7471 to 49.8100, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 20:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,280 | $44.33 | $56,742.40 |
DisclosureSEC source: 0001062993-25-011400 · form4.xml · nonDerivative · entry 2 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 3,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,976 | $0.00 Strike: $44.33 | $0.00 |
DisclosureSEC source: 0001062993-25-002706 · form4.xml · derivative · entry 5 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 1,280 Underlying: Common Stock · 3,256 shares Expires 2025-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,860 | $65.96 | $122,690.62 |
DisclosureSEC source: 0001062993-25-002706 · form4.xml · nonDerivative · entry 3 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 1,976 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:49 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,976 | $44.33 | $87,596.08 |
DisclosureSEC source: 0001062993-25-002706 · form4.xml · nonDerivative · entry 2 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 3,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2025 Filed Feb 7, 2025 21:56 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 115 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001897 · form4.xml · derivative · entry 14 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 115 Underlying: Common Stock · 115 shares Expires not disclosed F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028. F11 · derivative.expiration_date: 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028. Read SEC document |
| February 03, 2025 Filed Feb 7, 2025 21:56 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 344 | $0.00 Strike: $72.05 | $0.00 |
DisclosureSEC source: 0001062993-25-001897 · form4.xml · derivative · entry 11 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 344 Underlying: Common Stock · 344 shares Expires 2025-02-03 F7 · derivative.exercise_date: 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029. Read SEC document |
| February 03, 2025 Filed Feb 7, 2025 21:56 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 2,415 | $0.00 Strike: $72.05 | $0.00 |
DisclosureSEC source: 0001062993-25-001897 · form4.xml · derivative · entry 3 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,415 Underlying: Common Stock · 2,415 shares Expires 2035-02-03 F1 · derivative.exercise_date: The option vests on the earlier of the one-year anniversary of the grant date or the date of Bio-Techne's annual meeting of shareholders. Read SEC document |
| February 03, 2025 Filed Feb 7, 2025 21:56 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 1,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001897 · form4.xml · nonDerivative · entry 2 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,040 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.